|drug239||Analogs, Prostaglandin E1 Wiki||1.00|
|drug3246||Standard therapeutic protocol Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D055371||Acute Lung Injury NIH||0.09|
There is one clinical trial.
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).
Description: To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 29. Respiratory failure is defined as endotracheal intubation and mechanical ventilation, extracorporeal membrane oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision making is driven solely by resource limitationMeasure: Proportion of subjects that are alive without respiratory failure at Day 29. Time: Day 29
Description: Improvement on the WHO Ordinal Scale for Clinical Improvement (8-point ordinal scale)Measure: WHO clinical Improvement Time: Day15 Day 22 and Day 29
Description: Proportion of subjects with normalization of fever and oxygen saturation throughMeasure: Normalization of Fever and Oxygen Time: Day 15, Day 22, and Day 29
Description: Percentage of subjects discharged from hospitalMeasure: Discharge from Hospital Time: Day 15 and Day 22
Description: Proportion of patients alive and free of respiratory failureMeasure: Patients alive and free of respiratory failure Time: Day 15, and Day 22
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports